Chronic hepatitis C: Management of side effects of treatment;Hépatite chronique C: Gestion des effets indésirables du traitement

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 8-9 C3, 2007, Pages

  Larrey, Dominique ^a   Couzigou, Patrice ^b   Denis, Jacques ^c  

^a HÔPITAL SAINT ELOI   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c CENTRE HOSPITALIER SUD FRANCILIEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAROXETINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BRONCHIOLITIS; CONFUSION; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; EPILEPSY; FATIGUE; FEVER; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEPATITIS C; HUMAN; HYPERTHYROIDISM; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LICHEN PLANUS; LUNG DISEASE; MEMORY DISORDER; MYALGIA; MYASTHENIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PATIENT COMPLIANCE; PATIENT EDUCATION; PERSONALITY DISORDER; PHOTOSENSITIZATION; PSORIASIS; PSYCHOSIS; QUALITY OF LIFE; RASH; RETINA HEMORRHAGE; SARCOIDOSIS; SIDE EFFECT; SKIN ABSCESS; SUICIDE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; VISUAL IMPAIRMENT;

EID: 35848934828     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(07)92559-2     Document Type: Article

References (73)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi V, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
3. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: randomized study of treatment duration and ribavirin dose. Ann lntern Med 2004;140:346-55.
4. Zeuzem S, Sarrazin C. What is the optimal treatment for naïve patients with chronic hepatitis C? In: Marcellin P. Management of patients with viral hepatitis. Paris:APHC;2007:49-63.
5. Castéra L, Morice Y, Grando V, Bon C, Dény P, Roulot D. Le virus de l'hépatite C de génotype 4 : caractéristiques épidémiologiques et réponse aux traitements antiviraux. Gastroenterol Clin Biol 2003;27:596-604.
6. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon alpha-2a and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858-66.
7. Bonny C, Fontaine H, Poynard T, Hezode C, Larrey D, Marcellin P, et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients wlth hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006;15:593-600.
8. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97-103.
9. Zeuzem S, Djago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P, Pegasys Study NR16071 Investigator Group. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127:1724-32.
10. McHutchison J, Manns M, Patel K, Poynard T, Lindsay K, Trépo C, Dienstag J, Lee W, Mak C, Garaud JJ, Albrecht J and the international hepatitis interventional therapy group. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-69.
11. Pawlotsky JM, Dhumeaux D. Traitement de l'hépatite C. Edition EDK, Paris, 2004.
12. Larrey D. Hépatite chronique C : quelles sont les recommandations en dehors du traitement antiviral ? Gastroenterol Clin Biol 2002;26:B283-B290.
13. Negro F. Steatosis and HCV: dangerous liaisons. In: Marcellin P. Management of patients with viral hepatitis. Paris:APHC;2007:111-9.
14. Davis GL. Alcohol in chronic hepatitis C: legal or prohibited. In: Marcellin P. Management of patients with viral hepatitis. Paris:APHC;2007:119- 32.
15. Vial T, Bailly F, Descotes J, Trépo C. Effets secondaires de l'interferon alpha. Gastroenterol Clin Biol 1996;25:283-91.
16. Larrey D. Suivi de l'hépatite chronique C traitée. Gastroenterol Clin Biol 1997;20:S99-S110.
17. Gournay J, Richou C. Traitement de l'hépatite chronique C : effets secondaires, tolérance et qualité de vie. Gastroenterol Clin Biol 2002;26:B60-B75.
18. Fried MW. Side-effects of therapy of hepatitis C and their management. Hepatology 2002;36:237-44.
19. Russo MW and Fried M. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-9.
20. Theal JJ, Toosi MN, Girlan L, Heslegrave RJ, Huet PM, Burak KW, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 2005;41:1305-12.
21. Piche T, Vanbiervliet G, Cherikh F, Antoun Z, Huet PM, Gelsi E, et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomized, double blind, placebo controlled study. Gut 2005;54:1169-73.
22. Larrey D. Y a-t-il un risque à prescrire du paracétamol chez les malades atteints d'hépatopathies aiguës ou chroniques ? Gastroenterol Clin Biol 2006;30:753-5.
23. e ed. Blackwell; London: (in press).
24. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11.
25. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316-26.
26. Roudot-Thoraval F, Abergel A, Allaert F, Bourlière M, Desmorat H, Fagnani F, et al. Hépavir, première étude observationnelle d'une cohorte de malades traités par interféron alpha-2a en monothérapie. Évaluation de l'asthénie et de ses répercussions sociales. Gastroenterol Clin Biol 2001;25:1061-6.
27. Foster GR. Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol 1999;31:250-4.
28. Remy AJ, Daures JP, Tanguy G, Khemissa F, Chevrier M, Lezotre PL, et al. Mesure de la qualité de vie chez les malades ayant une hépatite chronique virale C : validation d'un indicateur général et d'un indicateur spécifique. Gastroenterol Clin Biol 1999;23:1296-309.
29. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002;63:194-8.
30. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-9.
31. Musselman DL, Lawson DH, Gumnik JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of derpession induced by high-dose interferon alfa. N Engl J Med 2001;344:961-6.
32. Schaefer M, Schwaiger M, Garkish AS, Pich M, Hinzpeter A, Uebelhack R, et al. Prevention of interferon-alpha-associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42:788-9.
33. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007 (in press).
34. Bessis D, Luong MS, Blanc P, Chapoutot C, Larrey D, Guilhou JJ, et al. Straight hair associated with interferon-alpha plus ribavirin in hepatitis infection. Br J Dermatol 2002;147:392-393.
35. Taliani G, Billiotti E, Capanni M, Tozzi A, Bresci S, Pimpinelli N. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemother 2005;17:212-4.
36. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: A prospective controlled study. Clin Endocrinol 1999;50:503-9.
37. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86:1925-9.
38. Marazuela M, Garcia-Buey L, Gonzales-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol 1996;44:635-42.
39. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994;89:399-403.
40. Deutsch M, Dourakis S, Manesis EK, Gioustosi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alpha therapy. Hepatology 1997;26:206-10.
41. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993;18:253-7.
42. Poynard T, Marcellin P. Lee SS, et al. Randomized trial if interferon-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998;352:1426-32.
43. McHutchinson JG, Gordon ST, Schiff ER, et al for the Hepatitis International Therapy Group. Interferon α alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
44. Gaeta GB, Precone DF, Felaco FM, Bruno R, Spadero A, Stornaiuolo G, et al. Premature discontinuation of interferon and ribavirin for adverse effects: a multicentre survey in "real world" patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1633-9.
45. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004.
46. Reddy KR, Hadzyannis SJ, Diago M, Marcellin P, Lopez-Talavera JC, Wright TL. The influence of cumulative peginterferon alpha-2a (40 KDa) and ribavirin (RBV) exposure on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis. J Hepatol 2005;42:abst 596.
47. Bain V, Lee S, Peltekian K, Yoshida E, Deschënes M, Sherman M, et al. Exposure to ribarivin (RBV) predicts EVR and SVR in patients with HCV genotype 1 infection: analysis of the Canadian Pegasys expanded access program (EAP). Hepatology 2006;44:abst 388.
48. Talal AH, Weisz K, Hau T, Kreiswirth S, Dietrich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol 2001;96:2802-4.
49. Sulkowski M, Wasserman R, Brau N, et al .Once weekly recombinant human erythropoietin (epoietin-alfa) facilitates optimal ribavirin dosing in hepatitis C virus infected patients receiving interferon alfa-2b/ribavirin therapy. Hepatology 2006;44:abst 2001.
50. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Schiffman ML, Sulkowski MS, et al. Gastroenterology 2004;126:1302-11.
51. Sulkowski MS, Dieterich DT, Bini EJ, Brau N, Alvarez D, Dejesus E, Leitz GJ; for the HIV/HCV Coinfection Study Group. Epoetin alfa once weekly improves anemia in HIV/ hepatitis C-co-infected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 2005;39:504-6.
52. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alpha-2a plus ribavirin for chronic hepatitis virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
53. Thévenot T, Cadranel JF, Di Martino V, Pariente A, Causse X, Renou C, et al. A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C. Hepatology 2007;45:377-83.
54. Schiffman M, Rodriguez-Torres M, Gordon S, Palmer M, Pockros P, Trépo C, et al. Rapid virologic response (RVR) is enhanced by higher drug exposure among patients receiving taribavirin in combination with pegylated interferon alpha-2b for the treatment of HCV infection. Hepatology 2006; 44:Abts 1146.
55. Jacobson I, Pockros P, Benhamou Y, Esteban-Mur R, Lurie Y, Flisiak R, et al. Impact of taribavirin and ribavirin exposure on efficacy and anemia rates when combined with pegylated interferon alfa-2b in the treatment of chronic HCV. Hepatology 2006;44:abst 391.
56. Peck-Radosavljevic M, Wichlas M, Homnick-Kraml M, Kreil A, Hofer H, Jessner W, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon alfa. Gastroenterology 2002;123 :141-51.
57. Hubel K, Dale DL, Liles WC. Therapeutic use of cytokines to module phagocyte function for the treatment of infectious diseases: current of granulocyte colony-stimulating factor, granulocyte macrophage colonystimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 2002;185:1490-501.
58. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care cancer 2002;10:181-8.
59. Kountouras J, Boura P, Tsapas G. In vivo effect of granulocyte-macrophage colony-stimulating factor and interferon combination on monocyte-macrophage and T-lymphocyte functions in chronic hepatitis B leukocytopenic patients. Hepatogastroenterology 1998;45:2295-302.
60. Van Thiel DH, Fakuri H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995;42:907-12.
61. Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N. Effects on interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther 2000;6:149-54.
62. Carreno V, Martin J, Pardo M, Brotons A, Anchia P, Navas S, et al. Randomized controlled trial of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of chronic hepatitis C. Cytokine 2000;12:165-70.
63. Schiffman ML, Hofmann CM, Luketic VA, Sanyal AJ. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J Hepatol 1998;28:382-9.
64. McHutchison J, Afdhal N, Dusheiko G, Shiffman M, Rodriguez-Torres M, Sigal S et al. Eltrombopag, and oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia: results form a phase II placebo controlled, double-blind, dose-ranging study. Hepatology 2006;44:abst LB3.
65. Craig PI, Tapner M, Farrell GC. Interferon suppresses erythromycin metabolism in rats and human subjects. Hepatology 1993;17:230-5.
66. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 1986;22:610-2.
67. Williams SJ, Blaird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987;II:939-41.
68. Jonkman JHG, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Oosterhuis B. Effects of alpha interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 1989;27:795-802.
69. Pageaux GP, LeBricquir Y, Berthou F, Bressot N, Picot MC, Blanc F, et al. Effects of interféron-• on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1998;10:491-5.
70. Assenat E, Gerbal S, Vilarem MJ, Larrey D. Cytochromes P-450 inhibition by pegylated interferon alpha in a primary culture of human hepatocytes: mechanisms and clinical implications. J Hepatol 2002;36(Suppl 2):abst 254.
71. Pol S. Prise en charge de l'infection virale C chez les patients coinfectés par le VIH recevant un traitement antirétroviral. La Presse Médicale 2001;30:677-82
72. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al. Risk factor for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during-interferon-based therapy. AIDS 2004;18 :F21-F25.
73. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals. Incidence, mechanisms and management. Drug safety 2006;29:53-66.